527 related articles for article (PubMed ID: 15494896)
41. Cidofovir use in acyclovir-resistant herpes infection.
Martinez CM; Luks-Golger DB
Ann Pharmacother; 1997 Dec; 31(12):1519-21. PubMed ID: 9416391
[TBL] [Abstract][Full Text] [Related]
42. Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives.
Schalkwijk HH; Snoeck R; Andrei G
Biochem Pharmacol; 2022 Dec; 206():115322. PubMed ID: 36309081
[TBL] [Abstract][Full Text] [Related]
43. Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution.
Frangoul H; Wills M; Crossno C; Engel M; Domm J
Pediatr Transplant; 2007 Dec; 11(8):942-4. PubMed ID: 17976133
[TBL] [Abstract][Full Text] [Related]
44. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
45. Marine organisms as a therapeutic source against herpes simplex virus infection.
Vo TS; Ngo DH; Ta QV; Kim SK
Eur J Pharm Sci; 2011 Sep; 44(1-2):11-20. PubMed ID: 21782018
[TBL] [Abstract][Full Text] [Related]
46. A new promising candidate to overcome drug resistant herpes simplex virus infections.
Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
[TBL] [Abstract][Full Text] [Related]
47. Dendritic keratitis caused by an acyclovir-resistant herpes simplex virus with frameshift mutation.
Zhang W; Suzuki T; Shiraishi A; Shimamura I; Inoue Y; Ohashi Y
Cornea; 2007 Jan; 26(1):105-6. PubMed ID: 17198024
[TBL] [Abstract][Full Text] [Related]
48. [Herpes simplex virus hepatitis; rare in immunocompetent patients].
Ozokcu L; de Bruijckere LM; Jansen J; van den Berge M
Ned Tijdschr Geneeskd; 2009; 153():A55. PubMed ID: 19785845
[TBL] [Abstract][Full Text] [Related]
49. Interactions and management issues in HSV and HIV coinfection.
Ramaswamy M; Geretti AM
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):231-43. PubMed ID: 17402838
[TBL] [Abstract][Full Text] [Related]
50. The emergence of acyclovir resistance in mucocutaneous herpes simplex viral infections: implications for clinical practice.
Grodesky MJ
Nurse Pract; 1997 Jun; 22(6):155-6. PubMed ID: 9211458
[No Abstract] [Full Text] [Related]
51. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.
Bacon TH; Levin MJ; Leary JJ; Sarisky RT; Sutton D
Clin Microbiol Rev; 2003 Jan; 16(1):114-28. PubMed ID: 12525428
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and Biological Evaluation of Amidinourea Derivatives against Herpes Simplex Viruses.
Toscani A; Denaro R; Pacheco SFC; Biolatti M; Anselmi S; Dell'Oste V; Castagnolo D
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443515
[TBL] [Abstract][Full Text] [Related]
53. New strategies against drug resistance to herpes simplex virus.
Jiang YC; Feng H; Lin YC; Guo XR
Int J Oral Sci; 2016 Mar; 8(1):1-6. PubMed ID: 27025259
[TBL] [Abstract][Full Text] [Related]
54. In vitro antiviral activity of distamycin A against clinical isolates of herpes simplex virus 1 and 2 from transplanted patients.
Matteoli B; Bernardini S; Iuliano R; Parenti S; Freer G; Broccolo F; Baggiani A; Subissi A; Arcamone F; Ceccherini-Nelli L
Intervirology; 2008; 51(3):166-72. PubMed ID: 18663321
[TBL] [Abstract][Full Text] [Related]
55. Herpetic geometric glossitis: acyclovir resistant case in a patient with acute myelogenous leukemia.
Pereira CM; Souza CA; Correa ME
Indian J Pathol Microbiol; 2010; 53(1):133-4. PubMed ID: 20090244
[TBL] [Abstract][Full Text] [Related]
56. Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum.
Levin MJ; Weinberg A; Leary JJ; Sarisky RT
Pediatr Infect Dis J; 2001 Nov; 20(11):1094-7. PubMed ID: 11734722
[TBL] [Abstract][Full Text] [Related]
57. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
James SH; Prichard MN
Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
[TBL] [Abstract][Full Text] [Related]
58. Acyclovir susceptibility of herpes simplex virus isolates from transplanted and nontransplanted patients in Rio de Janeiro, Brazil.
Varella RB; Guimarães MA; Guimarães AC; Atalla A; Nucci M; Ramos-e-Silva M
Skinmed; 2012; 10(4):208-11. PubMed ID: 23008937
[TBL] [Abstract][Full Text] [Related]
59. Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice.
Sarisky RT; Bartus HR; Dennis SA; Quail MR; Nguyen TT; Wittrock RJ; Halsey WS; Bacon TH; Leary JJ; Sutton D
BMC Infect Dis; 2001; 1():24. PubMed ID: 11749671
[TBL] [Abstract][Full Text] [Related]
60. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease.
Erard V; Wald A; Corey L; Leisenring WM; Boeckh M
J Infect Dis; 2007 Jul; 196(2):266-70. PubMed ID: 17570114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
